pain
Pain · 2015–2015
2decisions
2medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| buprenorphine; oxycodone + naloxone Additional strengths for management of pain (buprenorphine patches) and non-cancer pain (oxycodone + naloxone tablets). | Jul 2015 | Deferred | no section in document |
| oxycodone hydrochloride Modified release oxycodone 5 mg strength for pain management in patients unresponsive to non-opioid analgesics. | Mar 2015 | Not recommended | none received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.